Milestone Pharmaceuticals Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing is an annual report, not a standalone fourth-quarter report. Amounts are in U.S. dollars unless noted. Milestone is a clinical-stage biopharmaceutical company developing etripamil, a self-administered nasal-spray calcium channel blocker; it had no products approved for sale.
Business context and development
- The lead program is etripamil for paroxysmal supraventricular tachycardia (PSVT). Phase 3 trials NODE-301, NODE-302 and NODE-303 were ongoing at year-end.
- Management expected top-line NODE-301 data in the middle of the first half of 2020. The trial’s pivotal analysis was planned around 150 adjudicated SVT events.
- The completed Phase 2 study reported conversion to sinus rhythm within 15 minutes in 87% of patients at the selected 70 mg dose, versus 35% with placebo. This was a controlled electrophysiology-lab study, not the at-home Phase 3 setting.
- Management planned a roughly 50-patient Phase 2 proof-of-concept study in atrial fibrillation with rapid ventricular rate in 2020. Angina development remained at an early planning stage.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense, net | $42.0 million | $16.8 million |
| General and administrative expense | $7.0 million | $3.1 million |
| Commercial expense | $8.9 million | $3.9 million |
| Total operating expenses | $57.9 million | $23.8 million |
| Operating loss | $57.9 million | $23.8 million |
| Interest income, net | $2.6 million | $0.7 million |
| Net loss | $55.2 million | $23.2 million |
| Net cash used in operating activities | $51.2 million | $21.0 million |
- At December 31, 2019, cash and cash equivalents were $119.8 million; short-term investments were nil. Total assets were $123.4 million and total liabilities were $8.5 million, including operating lease liabilities.
- The company reported no debt. It received $85.4 million in net IPO proceeds in May 2019; the filing says the proceeds had not been used by year-end.
- Management expected existing cash, cash equivalents and short-term investments to fund operations for at least 12 months, based on its then-current forecast. It anticipated continued losses and increasing expenses.
- Profit margins are not meaningful because the company reported no product revenue. The independent auditor issued an unqualified opinion on the financial statements.
Material changes versus 2018
- Total operating expenses increased 143%, driven mainly by increased Phase 3 and other development spending; R&D expense rose 149%.
- Net loss increased from $23.2 million to $55.2 million, while operating cash use increased from $21.0 million to $51.2 million.
- Cash and cash equivalents rose from $85.9 million to $119.8 million, largely reflecting the IPO financing. Preferred shares converted into common shares at the IPO.
Outlook, risks and notable items
- Management’s key near-term milestone was NODE-301 data; regulatory approval depended on successful clinical results and FDA and other regulatory review. The program relied on one pivotal efficacy trial, and the filing notes that further trials could be required.
- Material risks include clinical failure or delay, safety concerns, continued financing needs, dilution or constrained operations if additional funding is required, and dependence on third-party manufacturers, CROs and a sole-source nasal-spray device supplier.
- Phase 2 included three serious adverse events considered possibly related to etripamil, including second-degree AV block with hypotension that resolved. Nasal irritation and congestion were common; higher doses showed transient blood-pressure decreases.
- Commercialization remains unproven: the company had no sales organization or commercial manufacturing agreements. Market acceptance, reimbursement, pricing, competition and regulatory requirements are significant uncertainties.
- The filing reports no material legal proceedings and no off-balance-sheet arrangements. It adopted lease accounting standard ASC 842 in 2019, recording operating lease assets and liabilities; management said the adoption did not materially affect results or cash flows.
- There are inconsistent figures in the filing text: the audited statements and MD&A results table report 2019 net loss of $55.229 million, while another MD&A passage says $53.7 million. The balance sheet reports accumulated deficit of $113.499 million, while an MD&A passage says $111.8 million.
Most important facts for investors to verify
- NODE-301 results, the completion and safety data from NODE-302 and NODE-303, and whether regulators require additional efficacy or safety studies.
- Cash use, current liquidity and the assumptions behind management’s statement that funds would last at least 12 months.
- The conflicting net-loss and accumulated-deficit figures against the audited financial statements and any subsequent clarification.
- Manufacturing readiness, including backup supply for the nasal-spray device and commercial-scale supply agreements.
- Whether the proposed atrial-fibrillation study and planned commercialization preparations proceeded as expected.